Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 12Neoplasm, Residual 2Myeloproliferative Disorders 2Leukemia, Promyelocytic, Acute 2Sarcoma, Myeloid 1Recurrence 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Acute 1Leukemia, Monocytic, Acute 1Blast Crisis 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cytarabine 3venetoclax 2Cladribine 2quizartinib 1pegylated granulocyte colony-stimulating factor 1Razoxane 1Mitoxantrone 1Idarubicin 1Gemtuzumab 1Dexrazoxane 1Daunorubicin 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Sarcoma, Myeloid × Gemtuzumab × Clear all
NCT03589729 2026-05-22

Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers

M.D. Anderson Cancer Center

Phase 2 Recruiting
100 enrolled
MyeloidOther hematologic neoplasmSarcoma

Blast Crisis, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Sarcoma, Myeloid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡